Evidence map›Paper›PMID 38077373›Full record

ReviewFrontiers in immunology2023

Research progress on the immune microenvironment and immunotherapy in gastric cancer.

Pei Mou, Qing-Hua Ge, Rong Sheng, Teng-Fei Zhu, Ye Liu, Kai Ding

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Materials today. Bio · 2026
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Pei Mou *Changzheng Hospital of Naval Medical University, Shanghai, China.
Qing-Hua Ge *Department of Otolaryngology, Changzheng Hospital of Naval Medical University, Shanghai, China.
Rong Sheng *Department of Outpatient, Changzheng Hospital of Naval Medical University, Shanghai, China.
Teng-Fei ZhuDepartment of Anesthesiology, Changzheng Hospital of Naval Medical University, Shanghai, China.
Ye LiuDepartment of Blood Transfusion, Changzheng Hospital of Naval Medical University, Shanghai, China.
Kai DingDepartment of Gastroenterology, Changzheng Hospital of Naval Medical University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tumor microenvironment, particularly the immune microenvironment, plays an indispensable role in the malignant progression and metastasis of gastric cancer (GC). As our understanding of the GC microenvironment continues to evolve, we are gaining deeper insights into the biological mechanisms at the single-cell level. This, in turn, has offered fresh perspectives on GC therapy. Encouragingly, there are various monotherapy and combination therapies in use, such as immune checkpoint inhibitors, adoptive cell transfer therapy, chimeric antigen receptor T cell therapy, antibody-drug conjugates, and cancer vaccines. In this paper, we review the current research progress regarding the GC microenvironment and summarize promising immunotherapy research and targeted therapies.

Indexed as

ImmunoconjugatesStomach NeoplasmsHumansImmunotherapyImmunotherapy, AdoptiveTumor MicroenvironmentImmunoconjugatesgastric cancerimmune microenvironmentimmunityimmunotherapysingle-cell sequencing

Identifiers

PMID38077373
PMCPMC10701536

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.